This study aimed to investigate the neuroprotective effects of safinamide against cell death and autophagy in a 6-hydroxydopamine (6OHDA)-induced cell model of Parkinson’s disease (PD). The optimum concentration of 6OHDA to be treated on SH-SY5Y cells to induce significant cytotoxicity and autophagy was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and acridine orange stain, respectively. Subsequently, an MTT assay was used to evaluate safinamide cytotoxicity on SH-SY5Y cells. To determine the neuroprotective effects of safinamide against cell death and autophagy in 6OHDA-treated SH-SY5Y cells, MTT assay and acridine orange were employed, while enzyme-linked immunosorbent assay was performed to investigate the involvement of autophagy-related proteins. Results showed 6OHDA induced autophagy at 12.5–200 μM, and cell death at 12.5, 25, 100, and 200 μM. Safinamide showed about 10% cytotoxic effect on SH-SY5Y cells at the highest concentration tested (50 μM). Safinamide slightly increased cell viability and reduced the percentage of autophagic cells by 23–40% in the 6OHDA-induced SH-SY5Y cells. 6OHDA and safinamide had no effect on Atg3, Atg5, and Beclin-1 protein levels. In contrast, 6OHDA slightly increased Atg12, Atg16L1, and LC3A/B protein expressions, in which, safinamide slightly reduced these expressions (not statistically significant). Similarly, 6OHDA significantly increased Atg7 protein expression, while safinamide treatment significantly reduced its expression. The study concluded that safinamide regulated autophagy through Atg7 inhibition in a 6OHDA-induced PD cell model.
Yeo YWP, Brianna, Yap YJ, Ng KY, Chye SM, Ling APK, Ooi YY, Tiong YL, Koh RY. Neuroprotective effects of safinamide against autophagy in 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson’s disease. J Appl Pharm Sci. 2024. Online First. http://doi.org/10.7324/JAPS.2024.142043
1. Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. Can Med Assoc J. 2016;188(16):1157-65. https://doi.org/10.1503/cmaj.151179 | |
2. Heo JY, Nam MH, Yoon HH, Kim J, Hwang YJ, Won W, et al. Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson's disease. Curr Biol. 2020;30(2):276-91. https://doi.org/10.1016/j.cub.2019.11.079 | |
3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76. https://doi.org/10.1136/jnnp.2007.131045 | |
4. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012;2(4):a009357. https://doi.org/10.1101/cshperspect.a009357 | |
5. Wang B, Abraham N, Gao G, Yang Q. Dysregulation of autophagy and mitochondrial function in Parkinson's disease. Transl Neurodegener. 2016;5:19. https://doi.org/10.1186/s40035-016-0065-1 | |
6. Bette S, Shpiner DS, Singer C, Moore H. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737-45. https://doi.org/10.2147/TCRM.S139545 | |
7. Kulisevsky J. Emerging role of Safinamide in Parkinson's disease therapy. Eur Neurol Rev. 2014;9(2):108-12. https://doi.org/10.17925/ENR.2014.09.02.108 | |
8. Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Expert Rev Neurother. 2016;16(3):245-58. https://doi.org/10.1586/14737175.2016.1150783 | |
9. Safinamide. 2022 [cited 2022 Oct 14]. Available from: https://www.drugbank.ca/drugs/DB06654 | |
10. Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. JAMA Neurol. 2017;74(2):216-24. https://doi.org/10.1001/jamaneurol.2016.4467 | |
11. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18-23. https://doi.org/10.1212/WNL.67.7_suppl_2.S18 | |
12. Morari M, Brugnoli A, Pisanò CA, Novello S, Caccia C, Melloni E, et al. Safinamide differentially modulates in vivo glutamate and gaba release in the rat hippocampus and basal ganglia. J Pharmacol Exp Ther. 2018;364(2):198-206. https://doi.org/10.1124/jpet.117.245100 | |
13. Morsali D, Bechtold D, Lee W, Chauhdry S, Palchaudhuri U, Hassoon P, et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain, 2013;136(4):1067-82. https://doi.org/10.1093/brain/awt041 | |
14. Sadeghian M, Mullali G, Pocock JM, Piers T, Roach A, Smith KJ. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathol Appl Neurobiol. 2016;42(5):423-35. https://doi.org/10.1111/nan.12263 | |
15. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Trans Suppl. 2006;71:53-65. https://doi.org/10.1007/978-3-211-33328-0_7 | |
16. Li J, Ma L, Fan Y, Zhang Y, Sun D, Wu B. Crosstalk between 6-OHDA-induced autophagy and apoptosis in PC12 cells is mediated by phosphorylation of Raf-1/ERK1/2. Pharmazie. 2016;71(8):465-71. | |
17. Urano Y, Mori C, Fuji A, Konno K, Yamamoto T, Yashirugi S, et al. 6-Hydroxydopamine induces secretion of PARK7/ DJ-1 via autophagy-based unconventional secretory pathway. Autophagy. 2018;14(11);1943-58. https://doi.org/10.1080/15548627.2018.1493043 | |
18. Zhang S, Gui X-H, Huang L-P, Deng M-Z, Fang R-M, Ke X-H, et al. Neuroprotective effects of β-asarone against 6-hydroxy dopamine-induced Parkinsonism via JNK/Bcl-2/Beclin-1 pathway. Mol Neurobiol. 2016;53(1):83-94. https://doi.org/10.1007/s12035-014-8950-z | |
19. Yoo H-I, Ahn G-Y, Lee E-J, Kim E-G, Hong S-Y, Park S-J, et al. 6-Hydroxydopamine induces nuclear translocation of apoptosis inducing factor in nigral dopaminergic neurons in rat. Mol Cell Toxicol. 2017;13(3):305-15. https://doi.org/10.1007/s13273-017-0034-5 | |
20. Saito Y, Nishio K, Ogawa Y, Kinumi T, Yoshida Y, Masuo Y, et al. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic Biol Med. 2007;42(5):675-85. https://doi.org/10.1016/j.freeradbiomed.2006.12.004 | |
21. Vitiello L, Marabita M, Sorato E, Nogara L, Forestan G, Mouly V, et al. Drug repurposing for Duchenne muscular dystrophy: the monoamine oxidase B inhibitor safinamide ameliorates the pathological phenotype in mdx mice and in myogenic cultures from DMD patients. Front Physiol. 2018;9:1087. https://doi.org/10.3389/fphys.2018.01087 | |
22. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31. https://doi.org/10.4103/0976-0105.177703 | |
23. ISO 10993-5. 2009. Biological evaluation of medical devices-Part 5: tests for in vitro cytotoxicity. Geneva, Switzerland: International Organization for Standardization; 2009. | |
24. Müller T. Safinamide: an add-on treatment for managing Parkinson's disease. Clin Pharmacol. 2018;10:31-41. https://doi.org/10.2147/CPAA.S137740 | |
25. Walczak M, Martens S. Dissecting the role of the Atg12-Atg5-Atg16 complex during autophagosome formation. Autophagy. 2013;9(3):424-5. https://doi.org/10.4161/auto.22931 | |
26. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67-93. https://doi.org/10.1146/annurev-genet-102808-114910 | |
27. Huang SC, Adhikari S, Brownell JE, Calderwood EF, Chouitar J, D'Amore NR, et al. Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors. Bioorg Med Chem. 2020;28(19):115681. https://doi.org/10.1016/j.bmc.2020.115681 | |
28. Ioghen OC, Ceafalan LC, Popescu BO. SH-SY5Y cell line in vitro models for Parkinson disease research-old practice for new trends. J Integr Neurosci. 2023;22(1):20. https://doi.org/10.31083/j.jin2201020 | |
Year
Month